JP2022520105A5 - - Google Patents
Info
- Publication number
- JP2022520105A5 JP2022520105A5 JP2021547415A JP2021547415A JP2022520105A5 JP 2022520105 A5 JP2022520105 A5 JP 2022520105A5 JP 2021547415 A JP2021547415 A JP 2021547415A JP 2021547415 A JP2021547415 A JP 2021547415A JP 2022520105 A5 JP2022520105 A5 JP 2022520105A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- composition
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806604P | 2019-02-15 | 2019-02-15 | |
| US62/806,604 | 2019-02-15 | ||
| US201962925704P | 2019-10-24 | 2019-10-24 | |
| US62/925,704 | 2019-10-24 | ||
| PCT/US2020/018405 WO2020168271A1 (en) | 2019-02-15 | 2020-02-14 | Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520105A JP2022520105A (ja) | 2022-03-28 |
| JP2022520105A5 true JP2022520105A5 (enExample) | 2023-02-22 |
Family
ID=72044142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547415A Pending JP2022520105A (ja) | 2019-02-15 | 2020-02-14 | マスト細胞性胃炎、マスト細胞性食道炎、マスト細胞性腸炎、マスト細胞性十二指腸炎、および／またはマスト細胞性胃腸炎を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220135673A1 (enExample) |
| EP (1) | EP3923986A4 (enExample) |
| JP (1) | JP2022520105A (enExample) |
| KR (1) | KR20210126084A (enExample) |
| CN (1) | CN113747918A (enExample) |
| AU (1) | AU2020223365A1 (enExample) |
| BR (1) | BR112021015009A2 (enExample) |
| CA (1) | CA3130072A1 (enExample) |
| IL (1) | IL285430A (enExample) |
| MX (1) | MX2021009626A (enExample) |
| SG (1) | SG11202108833QA (enExample) |
| WO (1) | WO2020168271A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019022912A2 (pt) | 2017-05-05 | 2020-05-26 | Allakos Inc. | Métodos e composições para tratar doenças oculares alérgicas |
| MX2019013136A (es) * | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios. |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
| AU2021365008A1 (en) * | 2020-10-22 | 2023-06-08 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| WO2022187834A1 (en) * | 2021-03-03 | 2022-09-09 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| KR20250007535A (ko) * | 2022-04-22 | 2025-01-14 | 인히브릭스 바이오사이언스, 인크. | Siglec-8 결합 단백질 및 그 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2465873A1 (en) * | 2010-12-16 | 2012-06-20 | Deutsches Rheuma-Forschungszentrum Berlin | Eosinophils as a therapeutic target |
| KR20210125114A (ko) * | 2013-12-09 | 2021-10-15 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
| MX2019013136A (es) * | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios. |
-
2020
- 2020-02-14 BR BR112021015009-9A patent/BR112021015009A2/pt not_active IP Right Cessation
- 2020-02-14 KR KR1020217029121A patent/KR20210126084A/ko not_active Ceased
- 2020-02-14 CN CN202080028635.6A patent/CN113747918A/zh active Pending
- 2020-02-14 CA CA3130072A patent/CA3130072A1/en active Pending
- 2020-02-14 US US17/430,256 patent/US20220135673A1/en not_active Abandoned
- 2020-02-14 SG SG11202108833QA patent/SG11202108833QA/en unknown
- 2020-02-14 MX MX2021009626A patent/MX2021009626A/es unknown
- 2020-02-14 EP EP20756504.5A patent/EP3923986A4/en not_active Withdrawn
- 2020-02-14 AU AU2020223365A patent/AU2020223365A1/en active Pending
- 2020-02-14 JP JP2021547415A patent/JP2022520105A/ja active Pending
- 2020-02-14 WO PCT/US2020/018405 patent/WO2020168271A1/en not_active Ceased
-
2021
- 2021-08-08 IL IL285430A patent/IL285430A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP7436477B2 (ja) | ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用 | |
| JP2020518645A5 (enExample) | ||
| RU2730674C2 (ru) | Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1) | |
| US12527784B2 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
| JP2015509962A5 (enExample) | ||
| CN112512580B (zh) | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| AU2016330471B2 (en) | Antibodies that bind human cannabinoid 1 (CB1) receptor | |
| JP2022542472A5 (enExample) | ||
| CN111886252B (zh) | 促进胰岛细胞生长的方法 | |
| JP2020518638A5 (enExample) | ||
| JP2024534602A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2024540435A5 (enExample) | ||
| KR20250136391A (ko) | 병용 요법을 위한 방법 및 조성물 | |
| CN112007162B (zh) | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 | |
| KR20240012472A (ko) | 요로상피암 치료에 있어서 면역관문 억제제와 병용투여되는 항체-약물 접합체의 용도 | |
| HUE028585T2 (en) | Anti-ferrolein monoclonal antibodies and their use | |
| CA3181598A1 (en) | Combination drug for treating kidney cancer | |
| JP2021523117A5 (enExample) | ||
| AU2022321783A1 (en) | Pharmaceutical composition for treating small cell lung cancer | |
| WO2021063331A1 (zh) | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 | |
| JP2022520572A5 (enExample) | ||
| CN115279405B (zh) | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 | |
| JP2022553378A5 (enExample) |